Vaginal misoprostol for pre-abortion cervical priming : is there an optimal evacuation time interval?
OBJECTIVE: To determine the optimal evacuation time interval in the use of vaginal misoprostol for cervical priming before first trimester termination of pregnancy.
DESIGN: Prospective double-blind randomised study.
SETTING: Fertility Control Centre, National University Hospital, Singapore.
METHODS: Sixty healthy nulliparous women requesting legal termination of pregnancy between 6 and 11 weeks of gestation were randomly allocated to either the 400 microg or 600 microg misoprostol group. Vacuum aspiration was performed after three hours in the 400 microg group and at the end of two hours in the women given 600 microg misoprostol. Using Hegar's dilator, degree of cervical dilatation before operation was measured. Other parameters assessed included the amount of additional dilatation required (if < Hegar 8), pre-operative and intra-operative blood loss, and associated side effects.
RESULTS: For the 600 microg group, only five women (16.7%) achieved a cervical dilatation of > or = 8 mm, compared with 28 women (93.3%) in the 400 microg group. Using the 400 microg misoprostol group as a baseline, the odds ratio was 0.014 (95% CI 0.003-0.080) for 600 microg for successful pre-operative cervical dilatation of > or = 8 mm. The mean cervical dilatation for 400 and 600 microg misoprostol was 8.1 mm and 6.6 mm, respectively (P < 0.001). Despite the shorter evacuation time interval of two hours, the 600 microg dose was associated with an increase in side effects such as vaginal bleeding, abdominal pain and a fever of > 38.0 degrees C. However, other than abdominal pain, no significant differences in the frequency of these side effects were shown.
CONCLUSION: Use of 400 microg misoprostol with a minimal evacuation time interval of three hours still appears the optimal dosage and evacuation time for cervical priming before first trimester termination of pregnancy.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
1999 |
|---|---|
| Erschienen: |
1999 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:106 |
|---|---|
| Enthalten in: |
British journal of obstetrics and gynaecology - 106(1999), 3 vom: 01. März, Seite 266-9 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Singh, K [VerfasserIn] |
|---|
| Anmerkungen: |
Date Completed 11.08.1999 Date Revised 19.07.2019 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM103582797 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM103582797 | ||
| 003 | DE-627 | ||
| 005 | 20231222130705.0 | ||
| 007 | tu | ||
| 008 | 231222s1999 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0346.xml |
| 035 | |a (DE-627)NLM103582797 | ||
| 035 | |a (NLM)10426647 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Singh, K |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Vaginal misoprostol for pre-abortion cervical priming |b is there an optimal evacuation time interval? |
| 264 | 1 | |c 1999 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 11.08.1999 | ||
| 500 | |a Date Revised 19.07.2019 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a OBJECTIVE: To determine the optimal evacuation time interval in the use of vaginal misoprostol for cervical priming before first trimester termination of pregnancy | ||
| 520 | |a DESIGN: Prospective double-blind randomised study | ||
| 520 | |a SETTING: Fertility Control Centre, National University Hospital, Singapore | ||
| 520 | |a METHODS: Sixty healthy nulliparous women requesting legal termination of pregnancy between 6 and 11 weeks of gestation were randomly allocated to either the 400 microg or 600 microg misoprostol group. Vacuum aspiration was performed after three hours in the 400 microg group and at the end of two hours in the women given 600 microg misoprostol. Using Hegar's dilator, degree of cervical dilatation before operation was measured. Other parameters assessed included the amount of additional dilatation required (if < Hegar 8), pre-operative and intra-operative blood loss, and associated side effects | ||
| 520 | |a RESULTS: For the 600 microg group, only five women (16.7%) achieved a cervical dilatation of > or = 8 mm, compared with 28 women (93.3%) in the 400 microg group. Using the 400 microg misoprostol group as a baseline, the odds ratio was 0.014 (95% CI 0.003-0.080) for 600 microg for successful pre-operative cervical dilatation of > or = 8 mm. The mean cervical dilatation for 400 and 600 microg misoprostol was 8.1 mm and 6.6 mm, respectively (P < 0.001). Despite the shorter evacuation time interval of two hours, the 600 microg dose was associated with an increase in side effects such as vaginal bleeding, abdominal pain and a fever of > 38.0 degrees C. However, other than abdominal pain, no significant differences in the frequency of these side effects were shown | ||
| 520 | |a CONCLUSION: Use of 400 microg misoprostol with a minimal evacuation time interval of three hours still appears the optimal dosage and evacuation time for cervical priming before first trimester termination of pregnancy | ||
| 650 | 4 | |a Clinical Trial | |
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Abortion, Drug Induced | |
| 650 | 4 | |a Abortion, Induced | |
| 650 | 4 | |a Asia | |
| 650 | 4 | |a Biology | |
| 650 | 4 | |a Cervical Dilatation | |
| 650 | 4 | |a Comparative Studies | |
| 650 | 4 | |a Demographic Factors | |
| 650 | 4 | |a Developing Countries | |
| 650 | 4 | |a Endocrine System | |
| 650 | 4 | |a Family Planning | |
| 650 | 4 | |a Fertility Control, Postconception | |
| 650 | 4 | |a Misoprostol--administraction and dosage | |
| 650 | 4 | |a Physiology | |
| 650 | 4 | |a Population | |
| 650 | 4 | |a Population Dynamics | |
| 650 | 4 | |a Prostaglandins | |
| 650 | 4 | |a Prostaglandins, Synthetic | |
| 650 | 4 | |a Research Methodology | |
| 650 | 4 | |a Research Report | |
| 650 | 4 | |a Singapore | |
| 650 | 4 | |a Southeastern Asia | |
| 650 | 4 | |a Studies | |
| 650 | 4 | |a Time Factors | |
| 650 | 4 | |a Treatment | |
| 650 | 7 | |a Abortifacient Agents, Nonsteroidal |2 NLM | |
| 650 | 7 | |a Misoprostol |2 NLM | |
| 650 | 7 | |a 0E43V0BB57 |2 NLM | |
| 700 | 1 | |a Fong, Y F |e verfasserin |4 aut | |
| 700 | 1 | |a Prasad, R N |e verfasserin |4 aut | |
| 700 | 1 | |a Dong, F |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t British journal of obstetrics and gynaecology |d 1976 |g 106(1999), 3 vom: 01. März, Seite 266-9 |w (DE-627)NLM000037990 |x 0306-5456 |7 nnns |
| 773 | 1 | 8 | |g volume:106 |g year:1999 |g number:3 |g day:01 |g month:03 |g pages:266-9 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 106 |j 1999 |e 3 |b 01 |c 03 |h 266-9 | ||